Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TE23 poor prognosis male germ cell tumour chemotherapy trial
2004-000405-22Phase 2Completed
- Sponsor
- Medical Research Council
- Start
- Feb 2005
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of carboplatin, vincristine, bleomycin, etoposide and cisplatin in germ cell tumor (GCT) and Germ Cell Testicular Cancer (2 arms), sponsored by Medical Research Council. Primary endpoint: Response rate. Started Feb 2005; status: completed.
02
Drugs
carboplatinvincristinebleomycinetoposidecisplatin
03
Conditions
germ cell tumor (GCT)Germ Cell Testicular Cancer
Beyond the preview
Go deeper on 2004-000405-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000405-22.